Abstract:Introduction:Few studies have assessed the efficacy and safety of micafungin in patients with proven or probable invasive aspergillosis (IA). This was the aim of the current study, which was conducted in 22 hospitals in China, where micafungin was approved for treatment of IA in 2006.Methods:This was a non-comparative, phase IV open-label study (NCT02646774). Eligible patient were adults with proven or probable IA. Efficacy endpoints included rates of overall treatment success (primary endpoint) and clinical improvement, fungal clearance, mortality, and the site of Aspergillus infection (all secondary endpoints). Safety endpoints included incidences of treatment-emergent adverse events (TEAEs), serious AEs (SAEs), and adverse drug reactions (ADRs). These endpoints were reported descriptively with associated 95% confidence intervals (CI); no hypotheses were tested.Results:The study was discontinued early due to low patient recruitment, which did not allow for the planned sample size to be reached. In total, 68 patients were enrolled: 42 into the full analysis set (for efficacy) and 61 into the safety analysis set. All patients were Han Chinese; the majority were male (n=26; 61.9%) and 60 years of age (n=35; 83.3%). Rates of overall treatment success, clinical improvement, fungal clearance, and mortality were 45.2% (n=19/42; 95% CI: 29.85-61.33); 59.5% (n=25/42; 95% CI: 43.28-74.37), 80.0% (n=4/5; 95% CI: 28.36-99.49), and 7.1% (n=3/42; 95% CI: 1.50-19.48), respectively. All patients were diagnosed with pulmonary Aspergillus infection. Overall, 155 TEAEs and 8 SAEs were reported by 37 (60.7%) and 7 (11.5%) patients. The most common TEAEs were decreased platelet count and fatigue (both n=5; 8.2%) and the most common SAEs were intracranial hemorrhage and lung infection (n=3; 4.9% and n=2; 3.3%). Eight ADRs (n=6; 9.8%) were reported but all were completely remitted or remitting during follow-up.Conclusions:Results suggest that micafungin is efficacious and well-tolerated in patients with proven or probable IA in China. However, these findings should be interpreted with care, due to the small number of patients included in this study. Further comparative trials should be used to confirm the efficacy and safety of micafungin in patients with proven or probable IA.

Comment of respiratory profession on the evaluation of multidisciplinary application of micafungin

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

Comparative Evaluation of ATB FUNGUS 3 Procedure and CLSI M27-A2 Broth Microdilution Method for Antifungal Susceptibility Testing of Pathogenic Yeasts

Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: an Update from the CHIF-NET Study

Application and evaluation of topical amphotericin B for the treatment of respiratory fungal infections

Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study

Interpretation of guidelines for invasive pulmonary fungal disease

Efficacy and Safety of Micafungin for the Treatment of Patients with Proven or Probable Invasive Aspergillosis: A Non-Comparative, Multicenter, Phase IV, Open-Label Study.

The practice and evaluation of antifungal stewardship programs at a tertiary first-class hospital in China

Detection of relationship between pathogens of acute exacerbation of chronic obstructive pulmonary disease and comprehensive evaluation classification

Successful treatment of mixed pulmonary Aspergillus and Mucor infection using intrabronchial amphotericin B infusion: a case report and literature review

Reassessment of the role of combination antifungal therapy in the current era

[A study of 152 cases of pulmonary fungal infection: reevaluation of the microbiological spectra].

How to Interpret the Guidance Value of in Vitro Susceptibility Test of Anti-Fungal Drugs on Dinical Practice

In vitro antifungal activity of micafungin against clinical strains of Candida spp. and Aspergillus spp. isolated from China

Evaluation of Population Pharmacokinetic Models of Micafungin: Implications for Dosing Regimen Optimization in Critically Ill Patients

Gut-Derived Short-Chain Fatty Acids and Macrophage Modulation: Exploring Therapeutic Potentials in Pulmonary Fungal Infections

Fungemia: A Retrospective Clinical Analysis of 17 Patients

A Brief Introduction to Several Novel Antifungal Drugs

Chinese expert consensus on management of antifungal‐resistant dermatophytoses (2024 edition)

Analysis of antifungal susceptibility in vitro and fungi distribution in clinics